Compare LEG & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | OCUL |
|---|---|---|
| Founded | 1883 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2018 | 2014 |
| Metric | LEG | OCUL |
|---|---|---|
| Price | $10.23 | $8.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.50 | ★ $23.56 |
| AVG Volume (30 Days) | 2.3M | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ 145.31 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $5,203,900,000.00 | $1,990,000.00 |
| Revenue This Year | N/A | $7.93 |
| Revenue Next Year | $2.73 | $96.07 |
| P/E Ratio | $74.79 | ★ N/A |
| Revenue Growth | 1.37 | ★ 3.48 |
| 52 Week Low | $7.86 | $6.23 |
| 52 Week High | $13.00 | $16.44 |
| Indicator | LEG | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 50.44 |
| Support Level | $9.36 | $8.36 |
| Resistance Level | $10.73 | $9.93 |
| Average True Range (ATR) | 0.33 | 0.44 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 64.24 | 63.12 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the maximum of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.